How To Value A Biotechnology Company
- Topics:
- Valuation
- Tags:
- Biotechnology,
- Biotechnology Company,
- Clinical Trial,
- Deloitte LLP,
- Healthcare,
- Management,
- Risk,
- Strategy
- Source:
- Deloitte & Touche LLP
FREE Registration is required
Overview: The major risk to be quantified in the valuation of a biotechnology company is the risk of successfully completing clinical trials. In order to accurately asses the value of a biotech company, it is crucial to have an understanding of the clinical development process for human therapeutics - the costs, timing and other risks of undertaking clinical trials. Through the process of clinical development, the compounds identified by scientists are approved for human use (for specific purposes) by regulatory authorities.
(Is this item miscategorized? Does it need more tags? Let us know.)
Format: HTML | Date: Jan 2009 | Pages: 4



